NovoCure Stock Price, News & Analysis (NASDAQ:NVCR) $12.77 -0.22 (-1.69%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$12.48▼$12.9050-Day Range$11.13▼$17.0052-Week Range$10.87▼$120.03Volume1.46 million shsAverage Volume1.39 million shsMarket Capitalization$1.36 billionP/E RatioN/ADividend YieldN/APrice Target$45.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability NovoCure MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside254.6% Upside$45.29 Price TargetShort InterestHealthy8.68% of Float Sold ShortDividend StrengthN/ASustainability-1.15Upright™ Environmental ScoreNews Sentiment-0.08Based on 22 Articles This WeekInsider TradingSelling Shares$4,832 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.04) to ($1.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector382nd out of 948 stocksMedical Devices Industry8th out of 17 stocks 3.3 Analyst's Opinion Consensus RatingNovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $45.29, NovoCure has a forecasted upside of 254.6% from its current price of $12.77.Amount of Analyst CoverageNovoCure has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.68% of the float of NovoCure has been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in NovoCure has recently decreased by 6.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNovoCure does not currently pay a dividend.Dividend GrowthNovoCure does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNovoCure has received a 68.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Brain cancer medication", and "Cabozantinib" products. See details.Environmental SustainabilityThe Environmental Impact score for NovoCure is -1.15. Previous Next 1.1 News and Social Media Coverage News SentimentNovoCure has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for NovoCure this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for NVCR on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added NovoCure to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NovoCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,832.00 in company stock.Percentage Held by InsidersOnly 5.67% of the stock of NovoCure is held by insiders.Percentage Held by Institutions84.11% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NovoCure are expected to grow in the coming year, from ($2.04) to ($1.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovoCure is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovoCure is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoCure has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NovoCure Stock (NASDAQ:NVCR)NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Read More NVCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVCR Stock News HeadlinesDecember 3, 2023 | americanbankingnews.comFY2023 EPS Estimates for NovoCure Limited (NASDAQ:NVCR) Reduced by Leerink PartnrsDecember 2, 2023 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of "Moderate Buy" from BrokeragesDecember 6, 2023 | Financial Alphas (Ad)Lithium Discovery So BIG You Can't Miss it, Even From SpaceWith the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!December 2, 2023 | americanbankingnews.comEquities Analysts Offer Predictions for NovoCure Limited's FY2023 Earnings (NASDAQ:NVCR)December 2, 2023 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) to Post FY2023 Earnings of ($2.01) Per Share, HC Wainwright ForecastsDecember 1, 2023 | markets.businessinsider.comBuy Rating on NovoCure Amid Strategic Restructuring and Promising Clinical TrialsDecember 1, 2023 | americanbankingnews.comNovoCure Limited Expected to Post Q2 2024 Earnings of ($0.48) Per Share (NASDAQ:NVCR)December 1, 2023 | americanbankingnews.comNovoCure Limited Forecasted to Earn Q3 2024 Earnings of ($0.45) Per Share (NASDAQ:NVCR)December 6, 2023 | Financial Alphas (Ad)Lithium Discovery So BIG You Can't Miss it, Even From SpaceWith the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!November 29, 2023 | americanbankingnews.comSintx Technologies (NASDAQ:SINT) & NovoCure (NASDAQ:NVCR) Head-To-Head SurveyNovember 28, 2023 | marketwatch.comNovocure to Cut 13% of Workforce in RestructuringNovember 28, 2023 | markets.businessinsider.comNovocure To Reduce 13% Of Current Workforce - Quick FactsNovember 28, 2023 | msn.comNovocure to eliminate 13% of workforce in restructuring effortNovember 21, 2023 | finance.yahoo.comNovocure to Participate in 35th Annual Piper Sandler Healthcare ConferenceNovember 16, 2023 | seekingalpha.comNovoCure: Significant Upside Even Without A BreakthroughNovember 16, 2023 | finance.yahoo.comNovoCure Limited (NASDAQ:NVCR) institutional owners may be pleased with recent gains after 85% loss over the past yearNovember 3, 2023 | finance.yahoo.comIs Novocure Stock a Buy?October 30, 2023 | finance.yahoo.comThe NovoCure Ltd (NVCR) Company: A Short SWOT AnalysisOctober 28, 2023 | finance.yahoo.comNovoCure Limited (NASDAQ:NVCR) Q3 2023 Earnings Call TranscriptOctober 28, 2023 | markets.businessinsider.comNovoCure Earns Buy Rating Amid Promising Pipeline and Operational EfficiencyOctober 27, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on NovoCure (NVCR)October 26, 2023 | finance.yahoo.comWhy Novocure Stock Was Sick TodayOctober 26, 2023 | finance.yahoo.comNovoCure Ltd (NVCR) Reports Q3 2023 Financial ResultsOctober 26, 2023 | finance.yahoo.comNovoCure (NVCR) Q3 2023 Earnings Call TranscriptOctober 26, 2023 | seekingalpha.comNovoCure Limited 2023 Q3 - Results - Earnings Call PresentationOctober 26, 2023 | finance.yahoo.comNovocure Reports Third Quarter 2023 Financial ResultsOctober 15, 2023 | finance.yahoo.comNovocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023See More Headlines Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/26/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVCR CUSIPN/A CIK1645113 Webwww.novocure.com Phone441534756700FaxN/AEmployees1,320Year FoundedN/APrice Target and Rating Average Stock Price Target$45.29 High Stock Price Target$51.00 Low Stock Price Target$25.00 Potential Upside/Downside+254.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,530,000.00 Net Margins-39.14% Pretax Margin-36.86% Return on Equity-46.89% Return on Assets-16.89% Debt Debt-to-Equity Ratio1.44 Current Ratio6.67 Quick Ratio6.43 Sales & Book Value Annual Sales$537.84 million Price / Sales2.54 Cash FlowN/A Price / Cash FlowN/A Book Value$4.20 per share Price / Book3.04Miscellaneous Outstanding Shares106,860,000Free Float100,802,000Market Cap$1.36 billion OptionableOptionable Beta0.52 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. William F. Doyle (Age 61)Executive Chairman Comp: $1.52MMr. Asaf Danziger (Age 57)President, CEO & Director Comp: $1.7MMs. Ashley Cordova (Age 43)Chief Financial Officer Comp: $933.39kMr. Wilhelmus C. M. Groenhuysen (Age 65)Chief Operating Officer Comp: $1.01MMr. Pritesh Shah (Age 44)Chief Growth Officer Comp: $810.6kMr. Frank LeonardPresident of CNS Cancers U.S.Prof. Yoram Palti M.D. (Age 85)Ph.D., Founder & CTO Comp: $282.51kDr. Moshe Giladi Ph.D.Chief Science OfficerMs. Ingrid GoldbergVP of Investor RelationsMr. Barak Ben Arye (Age 47)General Counsel More ExecutivesKey CompetitorsUFP TechnologiesNASDAQ:UFPTAdaptHealthNASDAQ:AHCOPROCEPT BioRoboticsNASDAQ:PRCTArtivionNYSE:AORTNevroNYSE:NVROView All CompetitorsInsiders & InstitutionsWellington Management Group LLPSold 824 shares on 12/1/2023Ownership: 0.069%Banque Pictet & Cie SASold 20,805 shares on 11/27/2023Ownership: 0.035%Deutsche Bank AGSold 115,555 shares on 11/24/2023Ownership: 0.013%Walleye Capital LLCBought 1,900 shares on 11/21/2023Ownership: 0.000%Walleye Trading LLCBought 2,200 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions NVCR Stock Analysis - Frequently Asked Questions Should I buy or sell NovoCure stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NVCR shares. View NVCR analyst ratings or view top-rated stocks. What is NovoCure's stock price target for 2024? 8 brokerages have issued 12-month target prices for NovoCure's shares. Their NVCR share price targets range from $25.00 to $51.00. On average, they anticipate the company's stock price to reach $45.29 in the next year. This suggests a possible upside of 254.6% from the stock's current price. View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts. How have NVCR shares performed in 2023? NovoCure's stock was trading at $73.35 on January 1st, 2023. Since then, NVCR shares have decreased by 82.6% and is now trading at $12.77. View the best growth stocks for 2023 here. When is NovoCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our NVCR earnings forecast. How were NovoCure's earnings last quarter? NovoCure Limited (NASDAQ:NVCR) released its quarterly earnings results on Thursday, October, 26th. The medical equipment provider reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.05. The medical equipment provider had revenue of $127.30 million for the quarter, compared to analysts' expectations of $128.75 million. NovoCure had a negative net margin of 39.14% and a negative trailing twelve-month return on equity of 46.89%. NovoCure's quarterly revenue was down 2.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.25) EPS. What ETFs hold NovoCure's stock? ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include BlueStar Israel Technology ETF (ITEQ), VanEck Israel ETF (ISRA), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares U.S. Medical Devices ETF (IHI).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What is Asaf Danziger's approval rating as NovoCure's CEO? 17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees. What other stocks do shareholders of NovoCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ). Who are NovoCure's major shareholders? NovoCure's stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (14.94%), Baillie Gifford & Co. (6.38%), Morgan Stanley (1.02%), Palo Alto Investors LP (0.62%), Charles Schwab Investment Management Inc. (0.51%) and Northern Trust Corp (0.41%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle. View institutional ownership trends. How do I buy shares of NovoCure? Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:NVCR) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.